Companies · 2 Nov 2026
Which companies have the most medicines short?
464 company families report shortages across the sixteen countries we track. Marketing-authorisation holders are grouped into families (Hexal and 1 A Pharma count as Sandoz, Ratiopharm as Teva, Mylan as Viatris).
Top 20 by products short
Breadth vs depth
Each dot is a company family. Click a dot to open its page.
All companies
| Company | Listed | Products | Medicines | Countries | New 90d | Manufacturing | Demand |
|---|---|---|---|---|---|---|---|
| Viatris | VTRS · Nasdaq | 995 | 248 | 307 | 61% | 19% | |
| Teva | TEVA · NYSE / TASE | 903 | 289 | 300 | 72% | 9% | |
| Sandoz | SDZ · SIX Swiss | 599 | 198 | 252 | 59% | 22% | |
| Pfizer | PFE · NYSE | 491 | 122 | 86 | 41% | 22% | |
| Accord (Intas) | 484 | 151 | 107 | 59% | 28% | ||
| Stada | 349 | 140 | 95 | 56% | 35% | ||
| Zentiva | 340 | 159 | 65 | 76% | 19% | ||
| Fresenius Kabi | FRE · Xetra | 339 | 81 | 60 | 34% | 31% | |
| Apotex | 326 | 152 | 65 | 94% | 1% | ||
| Sun Pharma | SUNPHARMA · NSE | 250 | 77 | 25 | 55% | 17% | |
| Aurobindo | AUROPHARMA · NSE | 226 | 111 | 50 | 51% | 24% | |
| Towa (Pensa) | 4553 · Tokyo | 201 | 102 | 108 | 63% | 28% | |
| Krka | KRKG · Ljubljana | 187 | 67 | 69 | 52% | 14% | |
| Sanofi | SAN · Euronext Paris | 158 | 45 | 97 | 68% | 11% | |
| Jamp | 151 | 74 | 18 | 85% | 7% | ||
| Baxter | BAX · NYSE | 149 | 27 | 15 | 63% | 21% | |
| Sawai | 4887 · Tokyo | 148 | 68 | 27 | 22% | 20% | |
| Hikma | HIK · LSE | 126 | 44 | 12 | 14% | 46% | |
| Glenmark | GLENMARK · NSE | 105 | 39 | 30 | 51% | 9% | |
| Sanis | 98 | 54 | 16 | 95% | 3% | ||
| Cheplapharm | 86 | 28 | 28 | 47% | 36% | ||
| GSK | GSK · LSE | 85 | 38 | 37 | 35% | 43% | |
| Advanz (Amdipharm) | 81 | 24 | 14 | 41% | 18% | ||
| Nichi-Iko | 77 | 29 | 17 | 13% | 64% | ||
| Takeda | 4502 / TAK · Tokyo / NYSE | 76 | 10 | 8 | 6% | 35% | |
| Johnson & Johnson | JNJ · NYSE | 75 | 19 | 10 | 24% | 30% | |
| Neuraxpharm | 75 | 19 | 17 | 81% | 2% | ||
| Novartis | NOVN · SIX Swiss | 70 | 32 | 31 | 62% | 24% | |
| Bayer | BAYN · Xetra | 68 | 17 | 35 | 52% | 23% | |
| Biomed | 64 | 21 | 0 | 9% | 5% | ||
| Daiichi Sankyo | 4568 · Tokyo | 59 | 18 | 18 | 55% | 24% | |
| Orifarm | 59 | 40 | 27 | 27% | 5% | ||
| Medochemie | 56 | 14 | 10 | 11% | 0% | ||
| Pharmascience | 51 | 32 | 11 | 98% | 0% | ||
| Marcan | 51 | 16 | 1 | 2% | 0% | ||
| Doc Generici | 50 | 25 | 12 | 84% | 14% | ||
| B. Braun | 49 | 17 | 18 | 46% | 39% | ||
| AA Pharma | 46 | 26 | 17 | 100% | 0% | ||
| H E | 46 | 15 | 11 | 52% | 22% | ||
| Octapharma | 42 | 6 | 3 | 0% | 33% | ||
| Jv E | 42 | 1 | 0 | 100% | 0% | ||
| Kyowa Pharmaceutical | 42 | 16 | 9 | 5% | 24% | ||
| Novo Nordisk | NOVO B · Nasdaq Copenhagen | 41 | 8 | 3 | 17% | 9% | |
| Odan | 41 | 31 | 0 | 98% | 2% | ||
| Aspen | APN · JSE | 41 | 13 | 9 | 55% | 3% | |
| Sterop | 41 | 16 | 11 | 37% | 0% | ||
| Nipro | 8086 · Tokyo | 41 | 17 | 3 | 2% | 63% | |
| Dr. Reddy's | RDY · NYSE / NSE | 40 | 24 | 14 | 38% | 50% | |
| Organon | OGN · NYSE | 40 | 20 | 21 | 74% | 9% | |
| Laboratoire Riva | 40 | 23 | 0 | 85% | 3% | ||
| Kern Pharma | 40 | 30 | 22 | 0% | 0% | ||
| Bausch Health | BHC · NYSE / TSX | 39 | 30 | 17 | 61% | 19% | |
| Bracco | 38 | 6 | 1 | 33% | 62% | ||
| G.L. | 38 | 13 | 4 | 59% | 0% | ||
| Tatsumi Kagaku | 38 | 24 | 10 | 63% | 8% | ||
| Otsuka | 4578 · Tokyo | 37 | 4 | 2 | 25% | 55% | |
| Eli Lilly | LLY · NYSE | 37 | 12 | 11 | 0% | 27% | |
| Piramal Critical | 35 | 13 | 0 | 46% | 21% | ||
| Imuna Pharm | 35 | 4 | 0 | 43% | 0% | ||
| AbbVie | ABBV · NYSE | 34 | 15 | 3 | 29% | 29% | |
| Medical Valley | 34 | 8 | 2 | 80% | 13% | ||
| Orion | ORNBV · Nasdaq Helsinki | 34 | 24 | 10 | 80% | 0% | |
| Rowex | 34 | 19 | 22 | 58% | 33% | ||
| Takata Pharmaceutical | 33 | 17 | 8 | 3% | 0% | ||
| Aristo | 32 | 16 | 3 | 42% | 38% | ||
| Norgine | 32 | 3 | 21 | 24% | 0% | ||
| Gedeon Richter | RICHTER · Budapest | 31 | 11 | 13 | 41% | 22% | |
| Eql | 31 | 9 | 5 | 0% | 0% | ||
| Guerbet | 30 | 5 | 10 | 30% | 70% | ||
| Lukas Heil-Betriebsst | 30 | 0 | 30 | 0% | 0% | ||
| Roche | ROG · SIX Swiss | 29 | 14 | 3 | 56% | 11% | |
| Omega | 29 | 18 | 4 | 72% | 21% | ||
| Bgp | 29 | 18 | 9 | 69% | 17% | ||
| Holsten - | 29 | 3 | 3 | 69% | 31% | ||
| Menarini | 29 | 17 | 15 | 70% | 4% | ||
| Paladin | 28 | 17 | 0 | 64% | 0% | ||
| Grifols | GRF · BME Madrid / Nasdaq | 28 | 9 | 2 | 55% | 45% | |
| Ge | 28 | 6 | 24 | 50% | 6% | ||
| Merck & Co. (MSD) | MRK · NYSE | 27 | 14 | 11 | 33% | 25% | |
| Ferring | 27 | 7 | 5 | 43% | 29% | ||
| Sterimax | 26 | 17 | 1 | 13% | 26% | ||
| Boehringer Ingelheim | 26 | 5 | 8 | 13% | 43% | ||
| Celltrion Hungary | 26 | 8 | 19 | 0% | 91% | ||
| Fuji Pharma | 4554 · Tokyo | 26 | 11 | 3 | 35% | 50% | |
| Choseido | 26 | 13 | 2 | 38% | 8% | ||
| Somerset | 25 | 5 | 0 | 0% | 0% | ||
| Cinfa | 25 | 14 | 13 | 0% | 0% | ||
| Honzo Pharmaceutical | 25 | 0 | 2 | 0% | 0% | ||
| Nihon Generic | 25 | 11 | 13 | 8% | 52% | ||
| Alfresa Pharma | 25 | 8 | 0 | 0% | 52% | ||
| Jiangsu Hengrui | 24 | 6 | 1 | 100% | 0% | ||
| Pi | 24 | 18 | 16 | 0% | 0% | ||
| Grindeks Riga | 24 | 9 | 0 | 0% | 0% | ||
| Gland | 23 | 7 | 0 | 56% | 22% | ||
| Thea | 23 | 8 | 6 | 44% | 0% | ||
| Heumann Generica | 23 | 2 | 3 | 100% | 0% | ||
| Amneal | AMRX · Nasdaq | 22 | 7 | 1 | 0% | 0% | |
| Micro | 22 | 5 | 12 | 0% | 100% | ||
| Par | 22 | 4 | 12 | 0% | 0% | ||
| Natco | 22 | 12 | 0 | 41% | 5% | ||
| Phoenix Unlimited | 22 | 6 | 6 | 58% | 0% | ||
| Fuso Pharmaceutical | 4538 · Tokyo | 22 | 6 | 2 | 0% | 100% | |
| Auro | 21 | 12 | 2 | 55% | 40% | ||
| Pierre Fabre | 21 | 8 | 11 | 78% | 17% | ||
| Santen | 4536 · Tokyo | 21 | 6 | 6 | 75% | 0% | |
| Normon | 21 | 15 | 15 | 0% | 0% | ||
| T's Pharma | 21 | 5 | 3 | 0% | 0% | ||
| Padagis | 20 | 4 | 0 | 100% | 0% | ||
| Par Pharmaceutical (Endo) | 20 | 4 | 0 | 0% | 0% | ||
| Hormosan Gesellschaft | 20 | 5 | 9 | 15% | 85% | ||
| CSL | CSL · ASX | 20 | 8 | 1 | 12% | 24% | |
| Reig Jofre | 20 | 14 | 7 | 0% | 0% | ||
| Ibsa Slovakia | 20 | 3 | 0 | 0% | 0% | ||
| 日本赤十字社 | 20 | 0 | 0 | 0% | 0% | ||
| Karo | 19 | 11 | 14 | 56% | 44% | ||
| Fidia | 19 | 7 | 1 | 53% | 40% | ||
| Ibsa | 19 | 6 | 5 | 63% | 11% | ||
| Brown Burk | 19 | 5 | 0 | 0% | 0% | ||
| Bristol Myers Squibb | BMY · NYSE | 18 | 10 | 2 | 73% | 18% | |
| Lannett | 18 | 2 | 0 | 0% | 0% | ||
| Vantive | 18 | 0 | 0 | 0% | 0% | ||
| Almus | 18 | 11 | 2 | 94% | 6% | ||
| Alter | 18 | 13 | 5 | 0% | 0% | ||
| Egis Plc | 18 | 8 | 7 | 83% | 0% | ||
| Nissin Pharmaceutical | 18 | 8 | 7 | 44% | 33% | ||
| Shionogi | 4507 · Tokyo | 18 | 7 | 3 | 0% | 50% | |
| Eisai | 4523 · Tokyo | 17 | 6 | 0 | 0% | 82% | |
| Terumo | 4543 · Tokyo | 17 | 2 | 0 | 6% | 0% | |
| Japan Blood Products Organization | 17 | 0 | 4 | 29% | 47% | ||
| Torrent | TORNTPHARM · NSE | 16 | 1 | 0 | 0% | 0% | |
| Sivem | 16 | 7 | 0 | 81% | 0% | ||
| Septa | 15 | 7 | 0 | 7% | 0% | ||
| Pro Doc | 15 | 6 | 3 | 90% | 0% | ||
| Mibe Arzneimittel | 15 | 4 | 3 | 7% | 0% | ||
| Kalceks | 15 | 12 | 4 | 50% | 50% | ||
| Holsten | 15 | 4 | 0 | 100% | 0% | ||
| Elite | 14 | 1 | 0 | 0% | 0% | ||
| Almirall | ALM · BME Madrid | 14 | 5 | 9 | 15% | 62% | |
| Istituto Biochimico | 14 | 6 | 0 | 100% | 0% | ||
| Specgx | 13 | 1 | 0 | 0% | 100% | ||
| Mint Pharmaceuticals | 13 | 9 | 0 | 100% | 0% | ||
| Searchlight | 13 | 9 | 0 | 50% | 0% | ||
| Icu Medical | 13 | 6 | 0 | 100% | 0% | ||
| Pb | 13 | 4 | 0 | 0% | 100% | ||
| Italiano Biochimico | 13 | 9 | 1 | 69% | 0% | ||
| Biotest | 13 | 5 | 1 | 15% | 15% | ||
| Pro.Med.Cs Praha | 13 | 9 | 1 | 77% | 0% | ||
| Avansor | 13 | 6 | 0 | 0% | 0% | ||
| Tsuruhara | 13 | 5 | 5 | 15% | 8% | ||
| 小島漢方 | 13 | 1 | 0 | 0% | 0% | ||
| 岩城製薬 | 13 | 11 | 1 | 62% | 31% | ||
| Alvogen | 12 | 1 | 0 | 0% | 0% | ||
| Nora | 12 | 4 | 0 | 100% | 0% | ||
| So.Se.Pharm Societa' | 12 | 9 | 2 | 42% | 8% | ||
| Pharmacare | 12 | 5 | 1 | 8% | 0% | ||
| Serra Pamies | 12 | 5 | 1 | 0% | 0% | ||
| Medreg S.R.O. | 12 | 8 | 6 | 33% | 0% | ||
| Hisamitsu | 4530 · Tokyo | 12 | 3 | 1 | 17% | 42% | |
| Rubicon Research | 11 | 1 | 0 | 0% | 0% | ||
| Epic | 11 | 0 | 0 | 44% | 0% | ||
| Chartwell Molecular | 11 | 2 | 0 | 0% | 0% | ||
| Solco | 11 | 2 | 0 | 0% | 0% | ||
| Vertical | 11 | 1 | 0 | 0% | 0% | ||
| Ge Buchler | 11 | 3 | 1 | 0% | 60% | ||
| Substipharm | 11 | 6 | 2 | 22% | 11% | ||
| Monico | 11 | 3 | 1 | 91% | 9% | ||
| I.B.N. Savio | 11 | 5 | 2 | 27% | 73% | ||
| Medac Gesellschaft | 11 | 5 | 3 | 20% | 50% | ||
| Tillomed | 11 | 7 | 5 | 71% | 29% | ||
| Hcs | 11 | 8 | 4 | 73% | 0% | ||
| Cooper Consumer | 11 | 6 | 6 | 78% | 11% | ||
| Pharmaselect International | 11 | 6 | 1 | 91% | 9% | ||
| Mepha | 11 | 10 | 4 | 0% | 0% | ||
| Mundipharma | 11 | 4 | 6 | 0% | 100% | ||
| Kalceks Riga | 11 | 8 | 0 | 27% | 0% | ||
| Omega A.S. | 11 | 2 | 4 | 73% | 0% | ||
| Evolan | 11 | 7 | 4 | 100% | 0% | ||
| Meiji | 2269 · Tokyo | 11 | 7 | 5 | 0% | 73% | |
| キョーリンリメディオ | 11 | 8 | 4 | 0% | 91% | ||
| Kindos | 10 | 1 | 0 | 100% | 0% | ||
| Sagent | 10 | 4 | 0 | 43% | 0% | ||
| Chiesi | 10 | 6 | 6 | 100% | 0% | ||
| Merck | 10 | 7 | 0 | 25% | 50% | ||
| Knight Therapeutics | 10 | 8 | 5 | 20% | 0% | ||
| Pharmaxis Europe | 10 | 3 | 2 | 57% | 0% | ||
| Ursapharm Arzneimittel | 10 | 6 | 0 | 80% | 0% | ||
| Laboratoire Francais | 10 | 3 | 0 | 100% | 0% | ||
| Th A | 10 | 5 | 2 | 100% | 0% | ||
| Theramex Ireland | 10 | 2 | 5 | 17% | 83% | ||
| 小西製薬 | 10 | 0 | 0 | 0% | 0% | ||
| Ingenus | 9 | 5 | 0 | 0% | 0% | ||
| Meitheal | 9 | 6 | 0 | 0% | 0% | ||
| Erfa 2012 | 9 | 7 | 0 | 78% | 0% | ||
| Servier | 9 | 7 | 4 | 33% | 56% | ||
| AstraZeneca | AZN · LSE / Nasdaq | 9 | 5 | 3 | 25% | 25% | |
| Carinopharm | 9 | 1 | 1 | 100% | 0% | ||
| Omnivision | 9 | 8 | 2 | 67% | 22% | ||
| Xiromed | 9 | 1 | 0 | 100% | 0% | ||
| Alfasigma | 9 | 7 | 4 | 100% | 0% | ||
| Adamed S.L.U. | 9 | 5 | 4 | 0% | 0% | ||
| Falk | 9 | 3 | 1 | 25% | 75% | ||
| S.Med Handels | 9 | 3 | 0 | 0% | 0% | ||
| Wabosan Arzneimittelvertriebs | 9 | 5 | 0 | 78% | 11% | ||
| Curium Netherlands | 9 | 3 | 0 | 78% | 0% | ||
| Laboratorium G. | 9 | 4 | 0 | 0% | 0% | ||
| Ebb Medical | 9 | 6 | 3 | 0% | 0% | ||
| Kyowa Kirin | 4151 · Tokyo | 9 | 2 | 0 | 0% | 22% | |
| Teyro | 8 | 1 | 0 | 0% | 0% | ||
| Prinston | 8 | 1 | 0 | 0% | 0% | ||
| Caplin Steriles | 8 | 2 | 0 | 0% | 0% | ||
| Inforlife | 8 | 3 | 0 | 0% | 0% | ||
| Lupin | LUPIN · NSE | 8 | 2 | 1 | 100% | 0% | |
| Mantra | 8 | 5 | 2 | 0% | 0% | ||
| Ethypharm | 8 | 4 | 2 | 0% | 50% | ||
| Denk | 8 | 3 | 4 | 62% | 38% | ||
| Betapharm Arzneimittel | 8 | 3 | 0 | 100% | 0% | ||
| Telix Innovations | 8 | 1 | 0 | 71% | 0% | ||
| Dermapharm Aktiengesellschaft | 8 | 3 | 4 | 62% | 25% | ||
| Biosimilar Collaborations | 8 | 3 | 5 | 100% | 0% | ||
| Recordati | REC · Borsa Italiana | 8 | 6 | 3 | 29% | 0% | |
| Fisiopharma | 8 | 6 | 0 | 62% | 0% | ||
| Pharmatex | 8 | 3 | 0 | 50% | 50% | ||
| Opella | 8 | 6 | 4 | 83% | 17% | ||
| M Lnlycke | 8 | 1 | 0 | 0% | 0% | ||
| Vipharm O | 8 | 2 | 0 | 100% | 0% | ||
| Sumitomo Pharma | 4506 · Tokyo | 8 | 3 | 2 | 0% | 38% | |
| あすか製薬 | 8 | 5 | 2 | 12% | 62% | ||
| 太陽ファルマ | 8 | 2 | 3 | 25% | 0% | ||
| コーアイセイ | 8 | 1 | 2 | 0% | 75% | ||
| Granules | 7 | 0 | 0 | 0% | 0% | ||
| Sunrise | 7 | 0 | 0 | 0% | 0% | ||
| Xgen Djb | 7 | 4 | 0 | 0% | 100% | ||
| Rhodes L.P. | 7 | 1 | 0 | 0% | 0% | ||
| Trigen | 7 | 1 | 0 | 0% | 100% | ||
| Samsung Bioepis | 7 | 5 | 1 | 0% | 83% | ||
| Bendalis | 7 | 4 | 2 | 100% | 0% | ||
| Teofarma | 7 | 5 | 4 | 100% | 0% | ||
| Elpen Beiname | 7 | 1 | 0 | 100% | 0% | ||
| Kedrion | 7 | 2 | 0 | 0% | 29% | ||
| Bruschettini | 7 | 6 | 3 | 43% | 43% | ||
| Alfa Intes | 7 | 5 | 0 | 100% | 0% | ||
| Grindeks | 7 | 6 | 1 | 17% | 50% | ||
| Atnahs Netherlands | 7 | 5 | 4 | 33% | 0% | ||
| Bexal | 7 | 4 | 5 | 0% | 0% | ||
| Ferrer Internacional | 7 | 5 | 4 | 0% | 0% | ||
| Aurovitas Spain | 7 | 6 | 3 | 0% | 0% | ||
| Impexeco | 7 | 4 | 3 | 0% | 0% | ||
| Arzneimittel Graz | 7 | 5 | 2 | 29% | 0% | ||
| Ebewe Ges.M.B.H | 7 | 6 | 3 | 86% | 14% | ||
| Alternova A | 7 | 5 | 3 | 0% | 0% |
Showing the 250 largest. Smaller holders are listed on each medicine page.
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.